Trials / Completed
CompletedNCT01389310
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
Post-marketing Safety Surveillance Program in HIV-infected Children Exposed to Atazanavir in Europe
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 249 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to monitor adverse events in HIV-infected children \<18 years old who are exposed to Atazanavir in a real-world setting in Europe.
Conditions
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2011-07-08
- Last updated
- 2014-12-23
Locations
9 sites across 7 countries: Belgium, Germany, Italy, Romania, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01389310. Inclusion in this directory is not an endorsement.